Amylyx completes enrollment in phase 3 trial for post-bariatric hypoglycemia

March 24, 2026 7:00 AM

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced completion of enrollment in its pivotal phase 3 LUCIDITY clinical trial of avexitide for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found